Evaluation of the efficacy and safety of intravitreal injection of ranibizumab every other month for age-related macular degeneration

Evaluation of the efficacy and safety of intravitreal injection of ranibizumab every other month for age-related macular degeneration - Ranibizumab every other month for age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005691

Enrollment

Registered

2011-06-01

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration

Interventions

Duration:12 months Quantity:ranibizumab 0.5mg Number of injection: 6 times a year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with active age-related macular degeneration

Exclusion criteria

Exclusion criteria: severe glaucoma, inflammation disease, diabetic retinopathy

Design outcomes

Primary

Measure	Time frame
Variation on a logarithm of the minimum angle of resolution 12 months after the first intravitreal injection	—

Secondary

Measure	Time frame
The rate of complication 12 months after the first intravitreal injection Variation on a central retinal thickness	—

Countries

Japan

Contacts

Public ContactTomoko Sawada

Shiga University of Medical Science Department of Ophthalmology

tsawada@belle.shiga-med.ac.jp0775482276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026